Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: greedsgd_2000 who wrote (111)	9/15/2000 10:57:43 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 138

IMO, its a stretch to think that just because they are in CA they will be a target for CALPERS. I'm sure they do not intend to just invest in CA companies and even if they did, there are LOTS of other biotechs in the BAY area that will draw attention (and those investment $$) over HEPH. Good news today but the stock traded less than 1/3 of the avg. volume. Market cap. just too low for most instutional investors too even consider. Plus the float is only 2.7M shares. Calpers could eat all that for lunch. Not liquid enough. I am interested in their HIV technology, it seems to be on the right track. This is especially true given the high cost of standard treatments and the lack of financial means to pay for them in Africa. As you pointed out, they still have a nice pile of cash and do not seem to be burning thru that at too high a rate. However, the spending will increase as they take on more of the trial tasks and prepare for filings in the US and other countries. I do not currently own HEPH. FWIW, I saw an article in Signals mag (www.recap.com) that detailed the tech. Jim